Novel medical indication of Baclofen and other GABAB receptor specific agonists from University of Frankfurt Hospital
INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH
Baclofen applies as a prototype of GABAB receptor specific agonists. For over 30 years it has been used to treat spastic disorders because of its muscle-relaxing and analgetic properties. Later, GABAB receptor specific agonists of 2nd and 3rd generation have been developed including allosteric modulators of GABAB receptor such as CGP 7930 or GS 39783.
So far, known uses of (ant)agonists of GABAB receptors include the therapy of diseases of the neural system, like multiple sclerosis, but also of the alimentary system, lung, kidney and bile.
Scientists from the University Hospital of Frankfurt am Main found that baclofen significantly improves the medical therapy in a so far unknown field of medical application. Furthermore, the results implicate that other GABAB receptor specific agonists hold a comparative potential.
The new indication applies to a multitude of patients mainly in industrialised countries. According to the physicians this means an important enhancement of today´s possibilities of treatment for these patients.
- Improvement of conventional methods to treat diseases of the new indication field.
- Clinical studies and pharmacological data regarding side effects of treatment with baclofen or other GABAB receptor specific agonists are already available.
Experiments in cell culture and using models in mice proceeded successfully. First studies in patients showed very good results. A patent for Germany is applied for.
Licensing or assignment of the technology is possible as well as a cooperation for further development of the invention.
Additional data and contact information are provided in the attached pdf.